Molecular mechanism of indirubin-3'-monoxime and Matrine in the reversal of paclitaxel resistance in NCI-H520/TAX25 cell line

Chinese Medical Journal

Volumn 126, Issue 5, 2013, Pages 925-929

  Luo, Su Xia ^a   Deng, Wen Ying ^a   Wang, Xin Feng ^a   Lü, Hui Fang ^a   Han, Li Li ^a   Chen, Bei Bei ^a   Chen, Xiao Bing ^a   Li, Ning ^a  

^a Henan Tumor Hospital   (China)

Author keywords

Drug resistance; Indirubin 3' monoxime matrine; Paclitaxel

Indexed keywords

CISPLATIN; FLUOROURACIL; INDIRUBIN; INDIRUBIN 3 MONOXIME; MATRINE; MESSENGER RNA; MITOMYCIN; PACLITAXEL; SURVIVIN; TRANSCRIPTION FACTOR SOX; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME IMMUNOASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OPTICAL DENSITY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; WESTERN BLOTTING;

ALKALOIDS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; INHIBITOR OF APOPTOSIS PROTEINS; OCTAMER TRANSCRIPTION FACTOR-3; OXIMES; PACLITAXEL; QUINOLIZINES; SOXB1 TRANSCRIPTION FACTORS;

EID: 84875320111     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123583     Document Type: Article

References (30)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
2. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 384-388.
3. Pinedo HM, Longo DL, Chabner BA. Cancer chemotherapy and biological response modifiers; annual 16. Amsterdam: Elsevier Science BV; 1996: 57-67.
4. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 2002; 27: 119-126.
5. Childs S, Yeh RL, Hui D, Ling V. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res 1998; 58: 4160-4167.
6. Yano S, Sone S, Nishioka Y, Naito M, Tsuruo T, Ogura T. Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cell to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes. Jpn J Cancer Res 1994; 85: 194-203.
7. Hrycyna CA, Ramachandra M, Ambudkar SV, Ko YH, Pedersen PL, Pastan I, et al. Mechanism of action of human P-glycoprotein ATPase activity. Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites. J Biol Chem 1998; 273: 16631-16634.
8. Min YD, Yang MC, Lee KH, Kim KR, Choi SU, Lee KR. Protoberberine alkaloids and their reversal activity of P-gp expressed multidrug resistance (MDR) from the rhizome of Coptis japonica Makino. Arch Pharm Res 2006; 29: 757-761.
9. Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, et al. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J 1996; 15: 2685-2694.
10. Liu F, Liu S, He S, Xie Z, Zu X, Jiang Y. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells. Oncol Rep 2010; 23: 1469-1475.
11. Capalbo G, Rödel C, Stauber RH, Knauer SK, Bache M, Kappler M, et al. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther Onkol 2007; 183: 593-599.
12. Monzo M, Roseu R, Felip E, Aatudillo J, Sanchez JJ, Maestre J, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17: 2100-2104.
13. Ling X, Bernacki RJ, Brattain MG, Li F. Induction of survivin expression by taxol and (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 2004; 279: 15196-15203.
14. Weng D, Song X, Xing H, Ma X, Xia X, Weng Y, et al. Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett 2009; 273: 257-265.
15. Yang H, Fu JH, Hu Y, Huang WZ, Zheng B, Wang G, et al. Influence of SiRNA targeting survivin on chemosensitivity of H460/cDDP lung cancer cells. J Int Med Res 2008; 36: 734-747.
16. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol 2000; 227: 239-255.
17. Li XL, Eishi Y, Bai YQ, Sakai H, Akiyama Y, Tani M, et al. Expression of the SRY-related HMG box protein SOX-2 in human gastric carcinoma. Int J Oncol 2004; 24: 257-263.
18. Pesce M, Schöler HR. Oct-4: control of totipotency and germline determination. Mol Reprod Dev 2000: 55: 452-457.
19. Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. Oct-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 2007; 120: 1598-1602.
20. Ravichandran K, Pal A, Ravichandran R. Effect of indirubin-3-monoxime against lung cancer as evaluated by histological and transmission electron microscopic studies. Microsc Res Tech 2010; 73: 1053-1058.
21. Perabo FG, Landwehrs G, Frössler C, Schmidt DH, Mueller SC. Antiproliferative and apoptosis inducing effects of indirubin-3'-monoxime in renal cell cancer cells. Urol Oncol 2011; 29: 815-820.
22. Cao J, Fang QX, Suo ZH. Effect and mechanism of indirubin-3-monoxime against proliferation in bladder cancer. Shandong Med J (Chin) 2008; 48: 61-63.
23. Liang CZ, Zhang JK, Shi Z, Liu B, Shen CQ, Tao HM. Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Cancer Chemother Pharmacol 2012; 69: 317-331.
24. Zahler S, Liebl J, Fürst R, Vollmar AM. Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro. Angiogenesis 2010; 13: 239-249.
25. Zhen Y, Sørensen V, Jin Y, Suo Z, Wiedlocha A. Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MARK. Oncogene 2007; 26: 6372-6385.
26. Zhao B, Li B, Bai S, Shen L, Ren R, Jonas JB, et al. Effects of matrine on proliferation and apoptosis of cultured retinoblastoma cells. Graefes Arch Clin Exp Ophthalmol 2012; 250: 897-905.
27. Li GH, Pan CY, Sun FJ, Yin GP, Wang XR. The interference in correlated molecular mechanism obtained multi-drug resistance of mouse S180's tumor cell for different alkaloid. China J Chin Mater Med (Chin) 2005; 30: 1844-1848.
28. Dong JH, Wang ZM, Fu XH. Effects of silence survivin by RNAi on apoptosis of A549 cells and on sensitivity of A549 cells to paclitaxel. Cancer Res Prevent Treat 2010; 37.
29. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, et al. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to taxol resistance. Clin Cancer Res 2009; 15: 1326-1334.
30. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000; 24: 372-376.